🇺🇸 FDA
Patent

US 10196378

Inhibitors of BCR-ABL mutants and use thereof

granted A61PA61P35/00A61P35/02

Quick answer

US patent 10196378 (Inhibitors of BCR-ABL mutants and use thereof) held by THE REGENTS OF THE UNIVERSITY OF MICHIGAN expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Grant date
Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P35/00, A61P35/02